U.S. Midterm Election Sprint: AI Regulation, Healthcare, and Defense Emerge as Wall Street's Three Key Trading Themes
nashnova research
With U.S. midterms entering the final stretch and polls favoring Democrats for the House, Wall Street is positioning around three policy lines — AI regulation, healthcare subsidies, and the defense budget — with a potential 15% defense-spending cut standing as the most concrete sector shock scenario.
How much do midterms actually move markets?
JPMorgan strategist Dubravko Lakos-Bujas's team argues the midterm impact will be more nuanced and more stock-picker-friendly than the 2024 presidential election — less about the index, more about sectors.
Wells Fargo's data: the S&P 500 has risen in the 12 months after every midterm since 1946.
This means → midterms have never been a lasting drag on equities, but short-term sector divergence is where the real trade lies this time.
AI and tech stocks — how real is the regulatory risk?
Morgan Stanley U.S. policy head Ariana Salvatore says the election is not about an immediate crackdown on data centers — it is about laying the groundwork for potential 2029 legislation.
Trump's veto power can block adverse Democratic bills, which partly shields the fundamentals of Nvidia, Alphabet, Meta, and Microsoft.
Yet risks are not zero: data-center REITs — real-estate investment trusts that package data centers into tradable funds — and emerging cloud players face potential compute-tax proposals; meanwhile Bloom Energy, GE Vernova, and Cummins, off-grid power providers, could actually benefit from tighter policy.
Evercore ISI adds that congressional AI probes could create scrutiny risk for Intel, IBM, and MP Materials — companies that have received U.S. government equity stakes.
Healthcare — what could a Democratic flip deliver?
Wolfe Research policy head Tobin Marcus argues hospital stocks stand to gain if Democrats successfully reverse last year's Medicaid cuts.
In plain terms = Democrats' playbook is to use next year's debt-ceiling negotiations as leverage to extract healthcare concessions.
Jefferies flags near-term upside in Acadia Healthcare, HCA Healthcare, and Tenet; insurers Centene and Oscar Health may draw bids on expectations that Democrats will negotiate to restore enhanced ACA subsidies — though Jefferies sees the probability as low.
Defense — where does the 15% budget-cut risk come from?
Melius Research analyst Scott Mikus warns: if legislative gridlock forces the Pentagon to run on continuing resolutions all year, its budget effectively shrinks by 15%.
This means → this is the most quantifiable sector shock of the election — not a vague "tighter regulation" narrative, but a specific number.
JPMorgan counters that if Republicans hold both chambers, defense spending could rise, with L3Harris Technologies, Lockheed Martin, and Northrop Grumman as likely beneficiaries.
Whether a formal budget or stopgap measure can resolve the standoff within weeks of the vote will be the key confirmation point for defense-sector direction.
Financials, crypto, and real estate — what other election trades are in play?
Banks: Republicans favor lighter regulation; JPMorgan says a GOP sweep could lift Bank of America, Citigroup, and Wells Fargo. But Barclays analyst Jason Goldberg cautions that Fed and FDIC leaders may stay in their posts for years — items like bank stress tests are unlikely to change on election night.
Crypto: Democrats and a handful of Republicans blocked the CLARITY Act — a bill aimed at creating a clear regulatory framework for crypto — in September, sending Coinbase and Circle shares tumbling. A Democratic Congress would push odds of any crypto legislation even lower.
Real estate: the S&P 500 Homebuilders Index is down 25% from its mid-February peak; September median home-sale prices rose 1.6% year-over-year to $429,100, and climbing mortgage rates keep pressure on builders. PennyMac policy head Isaac Boltansky expects Congress to give housing more attention post-election, calling easing supply constraints a long-term bipartisan consensus.
市场有风险，内容仅供研究参考，不构成投资建议。